Immune Checkpoint Blockade

Targeting Programmed Death-1 (PD-1) and Its Ligand (PD-L1)

Immunologic checkpoint blockade with antibodies targeting PD-1 or one of its ligands, PD-L1, is showing promise as a method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types.1 While the first checkpoint inhibitor approved by the FDA in 2011 was ipilimumab, an antibody that targets cytotoxic [ Read More ]

Exploring Immune Checkpoint Blockade for Glioblastoma

The blockade of immune checkpoints is among the most promising approaches to activating therapeutic antitumor immunity Immune “checkpoints” refer to the numerous negative immunologic regulators (inhibitory pathways) that are crucial for maintaining self-tolerance (ie, the prevention of autoimmunity) and modulating the immune responses in peripheral tissues.1 Cytotoxic T-lymphocyte–associated antigen 4 [ Read More ]

Sign me up!